While the higher LC and symptomatic control rates in the SRS/SBRT group did not reach statistical significance—likely due to limited sample size—these trends emphasize the potential benefit of dose escalation tailored to tumor size and metastatic site.
← all excerpts
External Beam Radiation Therapy for Pheochromocytoma and Non-Head and Neck Paraganglioma: A Single-Institution Experience and Systematic Review.
1
—
—